Completed Studies - Publications and Other Outputs
AChEW - Attitudes to Chemotherapy in Elderly Women (01/01/2010 to 31/03/2013)
Publication
Specialist breast care and research nurses' attitudes to adjuvant chemotherapy in older women with breast cancer https://doi.org/10.1016/j.ejon.2011.03.011Publication
The treatment of early breast cancer in women over the age of 70 https://doi.org/10.1038/bjc.2011.234Publication
Adjuvant chemotherapy in elderly women with breast cancer (AChEW): an observational study identifying MDT perceptions and barriers to decision making https://doi.org/10.1093/annonc/mds642Publication
Adjuvant Chemotherapy in Elderly Women with breast cancer (AChEW): patients' perspectives on information giving and decision-making https://doi.org/10.1002/pon.3338
Age Gap - Bridging the age gap in breast cancer; improving outcomes for older women (01/07/2015 to 30/06/2018)
Publication
Bridging the Age Gap in Breast Cancer: Evaluation of decision support interventions for older women with operable breast cancer: protocol for a cluster randomised controlled trial http://dx.doi.org/10.1136/bmjopen-2016-015133Publication
Efficient development and usability testing of decision support interventions for older women with breast cancer https://doi.org/10.2147/PPA.S178347Publication
Bridging the Age Gap in Breast Cancer: Cluster randomised trial of the effects of two decision support interventions for older women with operable breast cancer on quality-of-life, survival, decision-quality and treatment choices https://doi.org/10.1093/bjs/znab005
AVALPROFS - Assessing the VALue to patients of PROgression Free Survival (01/12/2012 to 11/01/2016)
Publication
The value of progression-free survival to patients with advanced-stage cancer https://doi.org/10.1038/nrclinonc.2011.156Publication
Therapeutic aims of drugs offering only Progression Free Survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits https://doi.org/10.1007/s00520-016-3408-7Publication
Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study https://doi.org/10.1007/s00520-018-4273-3Poster
Assessing the VALue of PROgression Free Survival (AVALPROFS) posters/AVALPROFS at ASCO Palliative Care Conf 23-25 Oct 14.pdfPoster
Assessing the VALue to patients of PROgression Free Survival (AVALPROFS) Quality of Life Results posters/FinalQoLAVALSanDiego11.1.17.pdfPoster
Hoping against hope: Are patients' expectations and understanding about therapeutic aims of novel drugs similar to their oncologists? posters/Eposter AVALPROFS NCRI 2018.pdf
BRCA Direct - Development and piloting of a digital platform to deliver Clinically-Integrated, Clinician-Independent, Rapid, Digital, Genetic Susceptibility Biomarker Testing (01/02/2020 to 31/12/2022)
Publication
A digital pathway for genetic testing in UK NHS cancer patients: BRCA-DIRECT pilot study https://doi.org/10.1136/jmg-2022-108655Publication
BRCA-DIRECT digital pathway for diagnostic germline genetic testing within a UK breast oncology setting: a randomised, non-inferiority trial https://doi.org/10.1038/s41416-024-02832-2
Chemotherapy and Cognition - Feasibility study to examine breast cancer treatment and cognition (01/05/2013 to 21/11/2014)
Publication
The (mis)classification of chemo-fog - methodological inconsistencies in the investigation of cognitive impairment after chemotherapy https://doi.org/10.1007/s10549-005-9055-1Publication
A feasibility study exploring the role of pre-operative assessment when examining the mechanism of 'chemo-brain' in breast cancer patients https://doi.org/10.1186/s40064-016-2030-yPoster
Feasibility study to examine underlying mechanisms for "chemo-cog" posters/St Gallen poster.pdf Presented at St. Gallen International Breast Care Conference 2015
CU FITTER - Cancer survivors' experiences of a community-based cancer-specific exercise programme: results of an exploratory survey (01/07/2016 to 31/10/2016)
Publication
Cancer survivors' experiences of a community-based cancer-specific exercise programme: results of an exploratory survey https://doi.org/10.1007/s00520-018-4179-0Poster
Exercise levels and experiences of those attending CUFITTER a tailored exercise programme for people incancer recovery posters/CUFITTER BPOS poster 2017 V3.pdf Presented at British Psychosocial Oncology Society Conference 2017Poster
How to keep active with cancer? Cancer survivors' experiences of a tailored exercise programme CUFITTERTM: results of an explorative survey posters/BPS AC2017 Poster7660_HHarder.pdf Presented at British Psychological Society Conference 2017
DIAMOND Phase 1-4 - Development and pilot testing of a web-based decision aid for people with motor neurone disease considering a gastrostomy feeding tube (01/08/2021 to 28/02/2023)
Publication
Developing a web-based patient decision aid for gastrostomy in motor neuron disease: a study protocol https://bmjopen.bmj.com/content/9/12/e032364Publication
Development of 'Gastrostomy tube - Is it for me?', a web-based patient decision aid for people living with motor neurone disease considering having a gastrostomy tube placed https://www.tandfonline.com/doi/full/10.1080/21678421.2023.2220743Article
Development and pilot testing of a web-based decision aid for people with motor neurone disease considering a gastrostomy tube https://shore-c.sussex.ac.uk/dev/docs/The-DiAMoND-Study.pdfPoster
Development and pilot testing of a web-based decision aid for people with motor neurone disease considering a gastrostomy tube (DiAMoND Study) posters/Wheelwright_BAPEN2022.pdf Presented at British Association for Parenteral and Enteral Nutrition (BAPEN) conference 2022Poster
'Gastrostomy Tube: Is it for Me?' Development and pilot testing of a web-based patient decision aid for people with motor neurone disease considering a gastrostomy tube (DiAMoND Study) posters/Wheelwright_ALSMNDSympPoster2022.pdf Presented at International Symposium on ALS/MND 2022App
Gastrostomy tube - Is it for me? https://gastrostomychoice.co.uk/Patient Information Film
DiAMoND study - Social Media version film https://youtube.com/shorts/3BIYRqLLR5IPresentation
The DiAMoND decision aid: Supporting people living with motor neurone disease to make the difficult decision about having a gastrostomy tube Presented at Marie Curie Research Conference 2023Presentation
Co-production and pilot testing a web-based decision aid to support people with motor neurone disease considering a gastrostomy tube (DiAMoND Study) Presented at Palliative Care Congress 2023
Patient Information Film
The DiAMoND study: A decision aid to support people living with MND
ENDOPREDICT - Optimising decision-making about chemotherapy in breast cancer (16/07/2015 to 31/10/2016)
Publication
Enhancing decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing https://doi.org/10.1002/pon.4664Publication
The cost-effectiveness of EndoPredict to inform adjuvant chemotherapy decisions in early breast cancer https://doi.org/10.1016/j.hlpt.2018.12.001Poster
Enhanced decision-making about adjuvant chemotherapy in early breast cancer following EndoPredict testing posters/Final ESMO Endo22.8.17.pdf Presented at European Society for Medical Oncology conference 2017
Exemestane - Quality of Life in Intergroup Exemestane Study (IES) (01/02/2001 to 30/06/2007)
Publication
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer https://doi.org/10.1056/NEJMoa040331Publication
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(07)60200-1Publication
Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation https://doi.org/10.1038/bjc.2012.43Publication
Long-Term follow-up of the Intergroup Exemestane Study (IES) https://doi.org/10.1200%2FJCO.2016.70.5640
EXPECT - Expectations and Experience of Treatment in castrate resistant prostate cancer (05/01/2015 to 04/08/2015)
Publication
No man's land: information needs and resources of men with metastatic castrate resistant prostate cancer https://doi.org/10.1007/s00520-016-3358-0Poster
Gaps and inconsistencies: Information for men with metastatic castrate resistant prostate cancer (mCRPC) posters/Final EXPECT 2.9.15.pdf Presented at European Cancer Congress 2015
Extreqol - EXperiences of TREatment and Quality Of Life of men with mCRPC (01/07/2016 to 30/06/2018)
Publication
Patient reported outcomes in metastatic castrate-resistant prostate cancer https://doi.org/10.1038/nrclinonc.2016.100Publication
EXTREQOL identifies ongoing challenges in maximising quality of survival in men with mCRPC https://doi.org/10.1016/j.clon.2018.02.001Publication
Treatment experiences, information needs, pain and quality of life in men with mCRPC: Results from the EXTREQOL study https://doi.org/10.1016/j.clon.2018.11.001Publication
Patients' and their partners' views of care and treatment provided for metastatic castrate resistant prostate cancer in the UK https://doi.org/10.1111/ecc.13140Poster
Survey Results on Managing Metastatic Castrate Resistant Prostate Cancer (mCRPC) posters/Poster for Baun 2017 final version 14.11.17.pdf Presented at British Association of Urological Nurses (BAUN) conference 2017Poster
Patients' and partners' views of treatment and care provided for metastatic castrate resistant prostate cancer (mCRPC) in the UK posters/135 X 90 ESMO 2018 S CATT.pdf Presented at European Society for Medical Oncology (ESMO) conference 2018
Go-Acupro - Group acupuncture for hot flushes in prostate cancer (GO-ACUPRO): feasibility for a pragmatic RCT (07/10/2019 to 07/10/2020)
Publication
The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer: a survey of UK practice https://doi.org/10.1177/0964528420959078
IMPACTOR - IMPact of AbemaCiclib on patienTs rOles and Responsibilities (01/09/2020 to 31/08/2023)
Poster
Early supportive interventions needed to reduce treatment burden of abemaciclib + endocrine therapy in metastatic breast cancer posters/IMPACTOR_POSTER_IPOS.pdf Presented at IPOS 2024
IMPARTER Phase 1 - IMproving PAtient undeRstanding of GEP TEst Results (01/10/2020 to 30/09/2021)
Publication
Phase 1 of an intervention to improve understanding of gene expression profiling tests in breast cancer: which is best, a patient information film or leaflet? https://doi.org/10.1007/s10549-021-06491-2Poster
An intervention to help improve understanding of gene expression profiling tests in breast cancer: Which is best, an information film or leaflet? posters/SABCSFINAL15nov21.pdf Presented at San Antonio Breast Cancer Symposium 2021
Jaw Study - Quality of life & communication in orthognathic (jaw straightening) surgery (04/09/2014 to 31/03/2016)
Publication
Quality of life and communication in orthognathic treatment https://doi.org/10.1080/14653125.2018.1458949
LIMBER - LIving with Metastatic Breast CancER (01/07/2021 to 30/11/2022)
Publication
Living with Metastatic Breast cancer (LIMBER): experiences, quality of life, gaps in information, care, and support of patients in the UK https://doi.org/10.1007/s00520-023-07928-8Poster
Exploring the support needs of women LIvingwith Metastatic Breast cancER: a qualitative analysis of the LIMBER survey posters/LimberQualPosterLJF.pdf Presented at Bench to Bedside conference 2024
Option - Ovarian Protection Trial in Hormone Receptor Negative Premenopausal Breast Cancer Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy (01/01/2004 to 31/12/2011)
Publication
The affect of goserelin on the QoL of women having chemotherapy for EBC: results from the OPTION trial https://doi.org/10.1016/j.breast.2020.05.009HCP Training Film
OPTION role plays
PEATY - Perceptions and Experiences of Abemaciclib and Endocrine TherapY (15/12/2021 to 31/08/2023)
Poster
Patients' experiences of abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC): a preliminary qualitative interview study posters/Fallowfield_PEATY_IPOS.pdf Presented at IPOS 2024
PEPSIN - Psychobiological Effects of Personalised Supportive Interventions (02/05/2017 to 20/04/2018)
Poster
PEPSIN Psychobiological Effects of Personalised Supportive INterventions: a feasibility study posters/PEPSIN BPOS 22nd feb.pdf Presented at British Psychosocial Oncology Society (BPOS) conference 2018
PRAGMATIC - Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (01/02/2020 to 31/03/2023)
Publication
Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Quality of Life and Service Use Results https://doi.org/10.1007/s00520-023-08002-zPublication
Patients' views and experiences on the Supported Self-Management/Patient initiatied follow up pathway for breast cancer https://doi.org/10.1007/s00520-023-08115-5Poster
Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC) posters/PRAGMATIC BPOS Poster 2020.pdf Presented at British Psychosocial Oncology Society (BPOS) Conference 2020Poster
Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC) posters/NCRI2021pragmaticInterviews.pdf Presented at National Cancer Research Institute (NCRI) Conference 2021Poster
Patients' experiences of a suppoRtedself-manAGeMentpAThwayIn breast Cancer (PRAGMATIC): 3 month Quality of Life Results posters/NCRI2021pragmaticQoL.pdf Presented at National Cancer Research Institute (NCRI) Conference 2021Presentation
Navigating a supportive self-management pathway for breast cancer - understanding the lived experience Presented at International Psyco-Oconcology Society (IPOS) World Congress 2022Presentation
Patients' experiences of a suppoRted self-manAGeMent pAThway In breast Cancer (PRAGMATIC): Interview results Presented at European Society for Medical Oncology (ESMO) Conference 2022Presentation
The PRAGMATIC Study Presented at Brighton Breast Day 2023
PrefHer - Preference for Herceptin SC or IV administration (01/07/2010 to 31/12/2014)
Publication
Patient preference for subcutaneous versus intravenous administration of trastuzumab in patients with early breast cancer (PrefHer study): a phase 2 randomised, multicenter, international trial https://doi.org/10.1016/S1470-2045(13)70383-8Publication
Intravenous versus Subcutaneous Drug Administration. Which do Patients Prefer? A Systematic Review https://doi.org/10.1007/s40271-014-0075-yPublication
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, twocohort PrefHer study https://doi.org/10.1093/annonc/mdu364Publication
Implications of subcutaneous or intravenous delivery of trastuzumab; further insight from patient interviews in the PrefHer study https://doi.org/10.1016/j.breast.2015.01.002Publication
Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial https://doi.org/10.1016/j.breast.2017.05.004Publication
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomized, two-cohort PrefHer study https://doi.org/10.1016/j.ejca.2017.08.019Poster
PATIENT PREFERENCE FOR SUBCUTANEOUS VERSUS INTRAVENOUS ADJUVANT TRASTUZUMAB: RESULTS OF THE PREFHER STUDY posters/Pivot et al StGallen2013 207 final.pdf Presented at St Gallen International Breast Cancer Conference 2013Poster
Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study posters/Fallowfield_PrefHer_Patients_ECC_poster_FINAL.pdfPoster
Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study posters/PrefHer ESMO Oct 2016.pdf Presented at European Society for Medical Oncology (ESMO) conference 2016Patient Information Film
PrefHer Training and Information DVDPatient Information Film
Herceptin TrastuzamabPatient Information Film
PrefHer Training DVD
PROACT - Patient Reported Outcomes in cancer, impact of Age and Carer/role demands associated with Treatment (02/03/2015 to 31/08/2019)
Publication
Patient reported outcome measures for cancer caregivers: a systematic review https://doi.org/10.1007/s11136-016-1239-0Publication
Patient reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review https://doi.org/10.1007/s11764-016-0580-1Publication
The pervasive nature of uncertainty - a qualitative study with patients with advanced cancer and their informal caregivers https://doi.org/10.1007/s11764-017-0628-xPublication
DEVELOPMENT AND VALIDATION OF THE PATIENT ROLES AND RESPONSIBILITIES SCALE IN CANCER PATIENTS https://doi.org/10.1007/s11136-018-1940-2Publication
DEVELOPMENT AND VALIDATION OF THE CAREGIVER ROLES AND RESPONSIBILITIES SCALE IN CANCER CAREGIVERS https://doi.org/10.1007/s11136-019-02154-4Publication
Insights into the use of social comparisons within an advanced cancer setting https://doi.org/10.1097/OR9.0000000000000006Poster
Patient reported outcome measures for cancer caregivers: A systematic review posters/Final PROACT ECCO 2.9.2015.pdfPoster
Uncertainty about the future for patients with advanced cancer and their informal caregivers: A qualitative view posters/PROACTqualitative poster final.pdf Presented at ASCO Cancer Survivorship Symposium 2015Poster
Measuring the impact of extended cancer survival on broader aspects of life and well being: The PROACT study posters/PROACT overview poster final.pdf Presented at ASCO Cancer Surviorship Symposium 2015Poster
Patient Reported Outcomes in Cancer, Impact of Age and Carer Role Demands Associated with Treatment (PROACT): Phase 1 Development of Scale Items posters/PROACT ISOQOL poster 2016.pdf Presented at International Society for Quality of Life Research Conference 2016Poster
Evaluation and validation of the proact measures for cancer patients and informal caregivers posters/PROACT ISPOR poster Nov 2017.pdf Presented at ISPOR 2017Poster
Patient Reported Outcomes in cancer, impact of Age and Carer role demands associated with Treatment (PROACT): The 'lucky' construct posters/Lucky Construct BPOS Poster.pdf Presented at British Psychosocial Oncology Society (BPOS) Conference 2017Poster
Evaluation of Construct and Structural Validity in the Patient Roles and Responsibilities Scale posters/Evaluation of Construct and Structural Validity in the PRRS.pdf Presented at International Society for Quality of Life Research Conference 2017Poster
Identifying trigger items from the Patient Roles and Responsibilities Scale posters/Indentifying trigger items from the PRRS.pdf Presented at British Psycosocial Oncology Society Conference 2020
PulMiCC - A Randomised trial of Pulmonary Metastasectomy in Colorectal Cancer (01/06/2009 to 31/03/2020)
Publication
Pulmonary metastasectomy in colorectal cancer: Time for a trial https://doi.org/10.1016/j.ejso.2008.12.005Publication
Current concepts: pulmonary metastasectomy for colorectal cancerPublication
Pulmonary Metastasectomy in Colorectal Cancer: The PulMiCC Trial https://doi.org/10.1097/JTO.0b013e3181dca239Publication
Pulmonary metastasectomy in colorectal cancer: the PulMiCC trial http://dx.doi.org/10.1136/thoraxjnl-2011-200015Publication
Randomized Controlled Trial of Pulmonary Metastasectomy in Colorectal Cancer: PulMiCC International Is Open in Italy https://doi.org/10.1634/theoncologist.2012-0476Publication
Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC): a phase III, multi-centre clinical trial https://doi.org/10.1186/s13063-019-3837-yPublication
Rapid Response: Re: Colorectal cancer: summary of NICE guidance https://www.bmj.com/content/368/bmj.m461/rr-2Publication
The myth of pulmonary metastasectomy https://www.nature.com/articles/s41416-020-0927-2Publication
Reply to 'Comment on "The myth of pulmonary metastasectomy"' https://www.nature.com/articles/s41416-020-01062-6.Publication
Pulmonary Metastasectomy in Colorectal Cancer: Health Utility scores by EQ-3D-3L in a randomised controlled trial show no benefit from lung metastasectomy https://onlinelibrary.wiley.com/doi/epdf/10.1111/codi.15833Publication
The fallacy of large survival gains from lung metastasectomy in colorectal cancer https://doi.org/10.1016/S0140-6736(20)32760-4Publication
The Pulmonary Metastasectomy in Colorectal Cancer cohort study: Analysis of case selection, risk factors and survival in a prospective observational study of 512 patients https://doi.org/10.1111/codi.15651Publication
The Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC) burden of care study: Analysis of local treatments for lung metastases and systemic chemotherapy in 220 patients in the PulMiCC cohort https://doi.org/10.1111/codi.15833Publication
The Prospective Observational Cohort and the Nested Randomized Controlled Trial in the Pulmonary Metastasectomy in Colorectal Cancer (PulMiCC Study) Question the Reliance on Existing Evidence for the Magnitude of Benefit From Lung Metastasectomy https://doi.org/10.1097/COC.0000000000000847Publication
Removal or ablation of asymptomatic lung metastases should be reconsidered https://doi.org/10.1136/bmj-2022-073042Publication
A prospective multicentre cohort study of colorectal lung metastasectomy with a nested randomized controlled trial: the key points from the pulmonary metastasectomy in colorectal cancer study https://doi.org/10.1093/ejcts/ezae216Poster
Patients' views on the PulMiCC trial information: Results from a survey posters/Accept decline CTM conference May 2017 final.pdf
REFLECTIONS - REmote Follow-up consultations: Lessons and Experiences during Covid-19 Time In ONcology Services (01/09/2020 to 28/02/2021)
Poster
Oncologists and patients believe more training is needed in telehealth and carers and nurses need inclusion posters/NCRI2021reflections.pdf Presented at National Cancer Research Institute (NCRI) conference 2021
Related - Patient related Outcome Study for Phase II Study of prophylactic octreotide (01/02/2014 to 11/04/2018)
Publication
The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer https://doi.org/10.1007/s10549-020-05798-wPoster
Measuring diarrhoea in a cancer setting: the importance of patient-reported tools posters/BPOSrelatedFeb20.pdf Presented at British Psychosocial Oncology Society (BPOS) conference 2020
TRUSTING Workshops 2020-21 Evaluation - Talking about Risk, UncertaintieS of Testing IN Genetics (19/11/2020 to 01/06/2022)
Publication
A systematic review of communication interventions for healthcare professionals discussing genetic testing in a breast cancer setting https://doi.org/10.1007/s10549-020-05741-zPublication
Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing https://doi.org/10.1007/s10549-020-05871-4Publication
Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING): development and evaluation of an educational programme for healthcare professionals about BRCA1 & BRCA2 testing https://doi.org/10.1038/s41416-022-01871-xPoster
TRUSTING: The development of a communication program for healthcare professionals talking about risk and uncertainty of testing in genetics posters/Trusting poster.pdf Presented at British Psycosocial Onocology Society (BPOS) conference 2021
TRUSTING Workshops 2022-23 Evaluation - Talking about Risk and UncertaintieS of Testing IN Genetics (07/02/2023 to 31/12/2023)
Publication
Roll-out of an educational workshop to improve knowledge and self-confidence of health professionals engaged in mainstreaming of breast cancer genetics https://doi.org/10.1371/journal.pone.0307301Poster
Roll out and influence on practice of the Talking about Risk, Uncertainties of Testing in Genetics (TRUSTING) educational programme posters/UKIBICSTrusting2024.pdf Presented at UK Interdisciplinary Breast Cancer Symposium 2024Poster
Roll out and influence of an educational program Talking about Risk, UncertaintieS of Testing IN Genetics (TRUSTING) posters/ASCO_TRUSTING_2024.pdf Presented at ASCO 2024 2024
Trusting Workshops 2024 Evaluation - Talking about Risk, UncertaintieS of Testing IN Genetics - 2024 Evaluation (02/01/2024 to 01/09/2024)
UKCTOCS - United Kingdom Collaborative Trial of Ovarian Cancer Screening (21/06/2000 to continuing)
Publication
Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones https://doi.org/10.1111/j.1471-0528.2006.01009.xPublication
Recruitment to multicentre trials - lessons from UKCTOCS: descriptive study https://doi.org/10.1136/bmj.a2079Publication
Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) https://doi.org/10.1016/S1470-2045(09)70026-9Publication
Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening https://doi.org/10.1038/sj.bjc.6605809Publication
Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort https://doi.org/10.1016/S1470-2045(10)70268-0Publication
Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials https://doi.org/10.1186/1745-6215-12-61Publication
Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening https://doi.org/10.1002/uog.12262Publication
Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS) https://doi.org/10.1111/1471-0528.12870Publication
Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening https://doi.org/10.1200%2FJCO.2014.59.4945Publication
Psychosocial factors associated with withdrawal from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) following one episode of repeat screening http://dx.doi.org/10.1097/IGC.0000000000000507Publication
Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al 10.1200/JCO.2015.64.1365Publication
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial https://doi.org/10.1016/S0140-6736(15)01224-6Publication
The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT https://doi.org/10.1038/bjc.2017.72Publication
The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) https://doi.org/10.1038/bjc.2017.222Publication
Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis 10.1097/GME.0000000000001377Publication
Ovarian cancer symptoms, routes to diagnosis and survival - Population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) https://doi.org/10.1016/j.ygyno.2020.05.002Publication
Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials - an ovarian cancer exemplar https://doi.org/10.1186/s13063-020-04968-xPublication
Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) https://doi.org/10.3390/cancers13040858Publication
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)00731-5Publication
Ovarian cancer population screening and mortality after long-term follow-up in the UK collaborative trial of ovarian cancer screening (UKCTOCS): a randomised controlled trial https://doi.org/10.1097/01.ogx.0000792624.55995.3ePublication
Mortality impact, risks, and benefits of general population screening for ovarian cancer: the UKCTOCS randomised controlled trial https://doi.org/10.3310/BHBR5832Publication
Insights from UKCTOCS for design, conduct and analyses of large randomised controlled trials https://doi.org/10.3310/CLDC7214Publication
Tumour stage, treatment, and survival of women with high-grade serous tubo-ovarian cancer in UKCTOCS: an exploratory analysis of a randomised controlled trial https://doi.org/10.1016/S1470-2045(23)00335-2Publication
Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer - an exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) https://doi.org/10.1016/j.ygyno.2023.11.005Publication
Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumout doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS https://doi.org/10.1016/j.ebiom.2024.105554
Yoga study - Evaluation of a specific yoga DVD for women following breast cancer surgery: An RCT (01/01/2008 to 31/12/2011)
Publication
Randomised controlled trials of yoga interventions for women with breast cancer: a systematic literature review https://doi.org/10.1007/s00520-012-1611-8Publication
Post-operative exercises after breast cancer surgery: results of a RCT evaluating standard care versus standard care plus additional yoga exercise https://doi.org/10.1016/j.eujim.2015.02.002Patient Information Film
Gentle Yoga Excercises Following Breast Cancer Surgery - Levels 1 - 3: Disc 1 - A guide to PosturesPatient Information Film
Gentle Yoga Excercises Following Breast Cancer Surgery - Levels 1 - 3: Disc 2 - The Class